Current reimbursement models in general do not accommodate many of the unique factors common among gene and cell therapies. In this second article of a three-part series, CRA’s Walter Colasante, Pascale Diesel, and Lev Gerlovin discuss the challenges to demonstrating value and addressing affordability and discuss options for payment models.
The authors wish to acknowledge the contributions of Stephanie Donahue and Michael Krepps to this article.
Click here to read the article.
CRA acquires bioStrategies Group, Inc.
Today CRA announced its acquisition of bioStrategies Group, Inc., a Chicago-based consulting firm focused on developing commercial strategies for healthcare...